Publications by authors named "V V Ovod"
Article Synopsis
- Phase 3 trials have shown that antiamyloid therapies are more effective in patients with milder Alzheimer disease, highlighting the need for plasma biomarkers in screening cognitively unimpaired individuals at risk of amyloid accumulation.
- This longitudinal study aimed to determine if a combination of specific plasma biomarkers could predict the onset of Aβ pathology in cognitively unimpaired individuals with low baseline brain Aβ levels.
- Results from multiple cohorts revealed that combining plasma %p-tau217 and Aβ42/40 levels significantly improved the detection of abnormal Aβ status, indicating a promising strategy for early intervention in Alzheimer's disease.
Alzheimer's disease biomarkers are crucial to understanding disease pathophysiology, aiding accurate diagnosis and identifying target treatments. Although the number of biomarkers continues to grow, the relative utility and uniqueness of each is poorly understood as prior work has typically calculated serial pairwise relationships on only a handful of markers at a time. The present study assessed the cross-sectional relationships among 27 Alzheimer's disease biomarkers simultaneously and determined their ability to predict meaningful clinical outcomes using machine learning.
View Article and Find Full Text PDFBackground: In MAPT (Multidomain Alzheimer Preventive Trial), a cognitive effect of multidomain intervention (MI) was showed in non-demented subjects with positive amyloid PET. However, screening eligible patients for multidomain intervention by PET is difficult to generalize in real-world settings.
Methods: MAPT study was a 3-year, randomized, placebo-controlled trial followed by a 2-year observational and optional extension.
Article Synopsis
- CSF amyloid-β peptide levels and tau phosphorylation are key biomarkers for Alzheimer's disease (AD), with a focus on p-tau181.
- A study analyzed various tau species and found that CSF pT217/T217 was a better predictor for brain amyloid presence via PET scans compared to traditional Aβ biomarkers.
- In individuals showing amyloid positivity, pT217/T217 was more strongly linked to amyloid levels, and in patients with AD symptoms, pT217/T217 and pT205/T205 showed better correlation with tau PET measures than p-tau181.
Objective: In Alzheimer's disease, hyperphosphorylated tau is associated with formation of insoluble paired helical filaments that aggregate as neurofibrillary tau tangles and are associated with neuronal loss and cognitive symptoms. Dual orexin receptor antagonists decrease soluble amyloid-β levels and amyloid plaques in mouse models overexpressing amyloid-β, but have not been reported to affect tau phosphorylation. In this randomized controlled trial, we tested the acute effect of suvorexant, a dual orexin receptor antagonist, on amyloid-β, tau, and phospho-tau.
View Article and Find Full Text PDF